- 著者
- Nobuo TAKEICHI Masaharu HOSHI Shozo IIDA Kimio TANAKA Yuka HARADA Zhaxybay ZHUMADILOV Nailya CHAIZHUNUSOVA Kazbek N. APSALIKOV Yoshihiro NOSO Toshiya INABA Kenichi TANAKA Satoru ENDO
- 出版者
- Journal of Radiation Research 編集委員会
- 雑誌
- Journal of Radiation Research (ISSN:04493060)
- 巻号頁・発行日
- vol.47, no.SupplementA, pp.A171-A177, 2006 (Released:2006-03-28)
- 参考文献数
- 25
- 被引用文献数
- 9
Chromosomal studies in peripheral lymphocytes from 63 residents near the Semipalatinsk nuclear test site, at ages of 52-63 years old, were performed in 2001-2002. A higher rate of chromosome aberrations was observed in the two contaminated villages, Dolon and Sarjal, compared with the control village, Kokpekti. Moreover, a relationship of frequency of cells with radiation induced chromosome aberrations and the previously estimated exposure dose was observed. Furthermore, apparent nuclear abnormalities (ANA) of thyroid follicular cells were studied in 30 out of 63 residents, who were examined for chromosome aberrations. A higher rate of ANA was also found in the residents in the exposed villages compared with those in the control village. These results suggest radiation effects both on the chromosomes in peripheral lymphocytes and on the follicular cells in the thyroid.
- 著者
- Dinara ZHARLYGANOVA Hironori HARADA Yuka HARADA Sergey SHINKAREV Zhaxybay ZHUMADILOV Aigul ZHUNUSOVA Naylya J. TCHAIZHUNUSOVA Kazbek N. APSALIKOV Vadim KEMAIKIN Kassym ZHUMADILOV Noriyuki KAWANO Akiro KIMURA Masaharu HOSHI
- 出版者
- Journal of Radiation Research 編集委員会
- 雑誌
- Journal of Radiation Research (ISSN:04493060)
- 巻号頁・発行日
- vol.49, no.5, pp.549-555, 2008 (Released:2008-09-19)
- 参考文献数
- 33
- 被引用文献数
- 18
It is known that bone marrow is a sensitive organ to ionizing radiation, and many patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) have been diagnosed in radiation-treated cases and atomic bomb survivors in Hiroshima and Nagasaki. The AML1/RUNX1 gene has been known to be frequently mutated in MDS/AML patients among atomic bomb survivors and radiation therapy-related MDS/AML patients. In this study, we investigated the AML1 mutations in radiation-exposed patients with MDS/AML among the residents near the Semipalatinsk Nuclear Test Site (SNTS), where the risk of solid cancers and leukemias was increased due to the radiation effects. AML1 mutations were identified in 7 (39%) of 18 radiation-exposed MDS/AML patients. In contrast, no AML1 mutation was found in 13 unexposed MDS/AML cases. The frequency of AML1 mutations in radiation-exposed patients with MDS/AML was significantly higher compared with unexposed patients (p < 0.05).We also found a significant correlation between individual estimated doses and AML1 mutations (p < 0.05). Considering these results, AML1 point mutations might be a useful biomarker that differentiates radio-induced MDS/AML from spontaneous MDS/AML.
- 著者
- Kensaku Aihara Tomohiro Handa Sonoko Nagai Kiminobu Tanizawa Kizuku Watanabe Yuka Harada Yuichi Chihara Takefumi Hitomi Toru Oga Tomomasa Tsuboi Kazuo Chin Michiaki Mishima
- 出版者
- 一般社団法人 日本内科学会
- 雑誌
- Internal Medicine (ISSN:09182918)
- 巻号頁・発行日
- vol.50, no.11, pp.1157-1162, 2011 (Released:2011-06-01)
- 参考文献数
- 32
- 被引用文献数
- 8 37
Objective We identified the prognostic relevance of pneumothorax in interstitial lung disease (ILD) patients and evaluated the efficacy and safety of autologous blood-patch pleurodesis. Methods We retrospectively reviewed 59 occurrences of pneumothorax in 34 ILD patients identified over a 12-year period. Results Air leakage ceased in 16 of 22 (72.7%) episodes after blood pleurodesis and in 11 of 14 (78.6%) episodes after chemical pleurodesis. Both the cure ratio and recurrence ratio in the cure episodes were comparable with those in the chemical pleurodesis group (p=0.99 and 0.99, respectively). In addition, there were no harmful events associated with blood pleurodesis. The median survival time after the first episode of pneumothorax was less than 9 months in patients with idiopathic interstitial pneumonia (IIP) and only around 3 years in the patients with other types of ILD, which have essentially favorable outcomes. Kaplan-Meier survival estimates were significantly worse in the patients with concomitant pneumomediastinum than in those without (p<0.05). A multivariate Cox regression analysis identified that the number of episodes of pneumothorax, IIP diagnosis and concomitant pneumomediastinum were independent predictors of death. Conclusion Autologous blood-patch pleurodesis is safe and worth considering as a first-line treatment for pneumothorax secondary to ILD. However, despite treatments, the prognosis after the onset of pneumothorax in ILD patients was found to be poor. In addition, concomitant pneumomediastinum may further worsen the prognosis.